NKTR-255 in combination with durvalumab following chemoradiation was well-tolerated in patients with non–small cell lung ...

Therapeutics and collaborators at The University of Texas MD Anderson Cancer Center presented late-breaking results from a Phase ...

Chavez, MD, discusses the efficacy of immunotherapy for the potential treatment of extensive-stage small cell lung cancers.

The top stories in non-small cell lung cancer (NSCLC) for 2024 included practice-changing results in EGFR-mutant disease, an ...

While presenting the Union Budget for 2024-25 in the Lok Sabha, Finance Minister Nirmala Sitharaman proposed to cut customs ...

In a move aimed at providing relief to cancer patients, the National Pharmaceutical Pricing Authority (NPPA) has directed ...

Akeso begins patient enrollment in phase 3 trial of ivonescimab combination as first-line therapy for biliary tract tumours, compared to durvalumab: China Monday, November 4, 2024 ...

The government instructed pharmaceutical companies to reduce prices on the anti-cancer drugs Trastuzumab, Osimertinib, and ...

NPPA directs manufacturers to reduce MRP of anti-cancer drugs following government's tax exemptions and duty reductions.

NPPA asks companies to revise MRP of three anti-cancer drugs and submit information: Gireesh Babu, New Delhi Tuesday, October 29, 2024, 16:15 Hrs [IST] The National Pharmaceutical ...

The government of India has mandated companies to reduce the prices of three anti-cancer drugs, Trastuzumab, Osimertinib, and ...